everal studies have indicated that concomitant use of clopidogrel and a proton-pump inhibitor (PPI) is associated with reduced antiplatelet efficacy of clopidogrel, and increased adverse cardiovascular events, after stent placement in patients with coronary heart disease (CHD). [1] [2] [3] [4] [5] In response to these findings, the US Food and Drug Administration updated the drug's label to warn that the effectiveness of clopidogrel is reduced when administered in combination with omeprazole. 6 Clopidogrel is a prodrug that requires hepatic biotransformation, which involves 2 CYP2C19-dependent steps to form its active metabolite. In turn, PPIs inhibit CYP2C19 enzyme activity to various degrees. 7, 8 Evidence from pharmacokinetic and pharmacodynamic studies suggests that PPIs decrease the antiplatelet efficacy of clopidogrel, probably by competitive inhibition of CYP2C19; however, recent studies show that concomitant use of clopidogrel and PPI was not related to an increased risk of clinical outcomes after percutaneous coronary intervention (PCI). 9 Furthermore, the results of the only randomized clinical trial to address this issue demonstrated similar cardiovascular risk regardless of whether subjects were assigned to clopidogrel alone or in combination with omeprazole. 10 We recently reported the frequency of CYP2C19 polymorphism in Japanese CHD patients; 11 in particular, the ratio of carriers with 2 loss-of-function alleles is 2-5% in Caucasians but 18-23% in Asian populations. 12- 14 Thus, we investigated whether concomitant use of a PPI and
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clopidogrel is associated with clinical outcomes in Japanese patients with CHD after stent implantation.
Editorial p 41 Methods
Study Population
The Kumamoto Intervention Conference Study (KICS) is a physician-initiated non-company-sponsored multicenter registry enrolling consecutive patients undergoing PCI in 16 centers in Japan. Between June 2008 and March 2009, 1,956 consecutive procedures were recorded on the PCI list. All consecutive patients who gave written informed consent were enrolled in this study. The exclusion criteria were (1) in-hospital death, (2) not on thienopyridines at the time of discharge, (3) re-intervention after first registration, and (4) planned staged interventional procedure. Finally, 1,270 patients after The subjects were assigned to 2 groups treated with (n=331) and without (n=939) a PPI. The decision to treat was the attending physician's in each hospital and was mostly because of a prior history of upper gastrointestinal ulcer or bleeding and complications of upper gastrointestinal symptoms (eg, heartburn or epigastric pain). We checked the compliance with all of the administrated drugs. The study protocol followed the guidelines of the ethics committee of each institution and written informed Figure 1 . Kaplan-Meier estimates of the cumulative rate of cardiovascular events, according to the PPI and non-PPI groups. The ratio of cardiovascular events was 3.3%, and 3.4% in the PPI and non-PPI groups, respectively. There was no significant difference in cardiovascular events between the PPI and non-PPI groups (P=0.58). PPI, proton-pump inhibitor. Figure 2 . Kaplan-Meier estimates of the gastrointestinal events, according to the PPI and non-PPI groups. The ratio of gastrointestinal events was 0.3%, and 1.8% in the PPI and non-PPI groups, respectively. There was a tendency to an increased risk of gastrointestinal events in the non-PPI compared with the PPI group (P=0.08).
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consent was given by each patient or the family of the subject.
Clinical Outcomes and Definition
The primary endpoint was defined as cardiovascular death, nonfatal myocardial infarction (MI), and ischemic stroke. The secondary endpoint was gastrointestinal event. Cardiovascular death was defined as death from MI, congestive heart failure, or documented sudden cardiac death. The universal definition of MI was used. 15 Diagnosis of ischemic stroke was made if the patient had clinical and radiological evidence of stroke without intracranial hemorrhage. Gastrointestinal event was identified by symptoms of heartburn, epigastric pain, hematemesis, or melena, and confirmed by endoscopic examination with obvious findings of ulcer or erosion, including bleeding, but excluding esophageal lesions, atrophic gastritis, and malignancies. Chronic kidney disease was defined as estimated glomerular filtration rate <60 ml · min -1 · 1.73 m -2 . For subjects experiencing more than 2 acute events, only the first event was considered in the analysis. The patients were followed up for 18 months until the endpoint.
Statistical Analysis
Continuous variables are expressed as the mean ± SD. Categorical variables are expressed as frequencies and percentages.
Comparison of continuous and categorical variables between PPI and non-PPI groups was performed by Student's t-test and chi-square test as appropriate, respectively. Estimates of the cumulative event rates were calculated by the Kaplan-Meier method, and PPI and non-PPI groups were compared by the log-rank test of the 18-month curves. Hazard ratio (HR) and 
Results
At the time of discharge, 331 patients were on a PPI (PPI group) and 939 patients were not (non-PPI group). Clinical characteristics of patients treated with or without a PPI are shown in Table 1A . Age was significantly higher in the PPI group (P=0.048). There were no significant differences between the PPI and non-PPI groups for the other baseline characteristics.
As shown in 
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associated with an increased risk of cardiovascular events in contrast to the negative drug interaction of PPI reported abroad. Patients with chronic kidney disease had a tendency of an increased risk of gastrointestinal events (P=0.09, Table 1C ).
Although the value of PPI use was not statistically significant, the HR for gastrointestinal events was low, so patients treated without PPI had an increased risk for gastrointestinal events during dual antiplatelet therapy (1 vs. 17 cases; HR, 0.21; 95%CI 0.02-1.60; P=0.13).
Regarding the choice of thienopyridine, the health insurance system in Japan does not allow the use of clopidogrel for patients with stable angina, unlike most other countries. Thus, in Japan ticlopidine as well as clopidogrel is often selected for CHD (ticlopidine, n=640; clopidogrel, n=630). In subgroup analysis performed for patients taking clopidogrel, there were no significant differences in baseline characteristics (Table 2A) . There was no significant difference in the ratio of cardiovascular death, MI, and ischemic stroke between the PPI and non-PPI groups (Table 2B ). There were no gastrointestinal events in the PPI group, and the non-PPI group had a tendency of an increased risk of gastrointestinal events compared with the PPI group (PPI vs. non-PPI, 0 vs. 9; Log-rank P=0.06). Table 2C shows the Cox proportional HRs for cardiovascular and gastrointestinal events in the clopidogrel arm. There were no significant predictors (PPI use, ACS, previous MI, diabetes, female sex, high age, chronic kidney disease, and stroke) for cardiovascular events. Although the Cox HRs for gastrointestinal events did not exhibit significant values, except for the PPI use, there were no gastrointestinal events in the PPI group of the clopidogrel arm.
In subgroup analysis of ACS patients, there were no significant differences in the other baseline characteristics, except for age and use of angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker, between the PPI and non-PPI groups (Table 3A) . There was no significant difference in the ratio of cardiovascular or gastrointestinal events (Table 3B) . Table 3C shows the Cox proportional HRs for cardiovascular and gastrointestinal events in ACS patients. There were no significant predictors for cardiovascular and gastrointestinal events in the subgroup analysis of the clopidogrel arm as well.
Discussion
The main finding of our study was that concomitant use of a thienopyridine and PPI did not increase the risk of adverse cardiovascular events after PCI. Subgroup analysis performed in patients taking clopidogrel also did not show an increased cardiovascular risk in the coadministration of a PPI. We previously evaluated the effects of gastric medicines on gastroduodenal injury in patients with CHD during antiplatelet therapy with aspirin and a thienopyridine derivative, and demonstrated that gastroduodenal damage associated with the use of antiplatelet agents occurred in the non-PPI group, including histamine H2-receptor antagonists, but there was no case of gastroduodenal damage in the PPI group. 16 Moreover, the expert consensus from ACCF, ACG, and AHA in 2010 recommends that PPIs are appropriate for patients with multiple risk factors for gastrointestinal bleeding who require antiplatelet therapy. 17 However, recent studies reported that coadministration of clopidogrel and a PPI is associated with a reduced effect on the platelet response to clopidogrel, 18 and an increased risk of adverse outcomes after stent placement in patients with ACS, 1-5 although some studies have shown conflicting data that the concomitant use of PPI and clopidogrel is not associated with an increased risk of cardiovascular events. 9,10, 19 Hulot et al reported by meta-analysis that conflicting results among the previous retrospective studies may be explained by differences in the types and/or levels of risk of CHD patients; 20 thus, a higher ratio of cardiovascular events is probably because of confounding, as patients on PPIs had a higher risk profile at baseline. In this study, there was no difference in the baseline characteristics of the patients except for age. With less influence of cardiovascular risk at baseline, our data indicated that the concomitant use of PPI and clopidogrel did not increase the risk of adverse clinical outcomes.
In the present study, although there was no significant difference between the PPI and non-PPI groups in the incidence of gastrointestinal events, there was a trend towards more gastrointestinal events in the non-PPI group. Among various PPIs, the intake of pantoprazole or esomeprazole is reported to be not associated with reduced platelet inhibition by clopidogrel as compared with patients without PPI. 21, 22 Rabeprazole, omeprazole, and lansoprazole are the only available PPIs in Japan. The KICS is a multicenter registry enrolling consecutive PCI cases, and the decision to treat with or without a PPI or which type of PPI to use was at the discretion of the attending physician in each hospital. As a basic guideline, we used a PPI for patients with a prior history of upper gastrointestinal lesions, complications of upper gastrointestinal symptoms, including heartburn or epigastric pain, or concomitant use of a nonsteroidal antiinflammatory drug, steroid, anticoagulant, or other antiplatelet agents. Despite this difficult situation with a high risk of occurrence or recurrence of gastrointestinal lesions, there were no serious cases in the PPI group compared with the non-PPI group. We cannot exclude the possibility that the small number of participants did not make a significant difference.
In the subgroup analysis of the clopidogrel arm, PPI coadministration did not show an increased risk of adverse clinical events. We previously reported the cardiovascular risk in clopidogrel-treated patients according to CYP2C19 polymorphism or PPI coadministration in a single center study. 19 The results showed that the CYP2C19 genotype is associated with reduced antiplatelet efficacy of clopidogrel and an increased risk for cardiovascular events; however, the adjunctive use of a PPI was not related to adverse clinical outcomes. These findings support the present results in the KICS multicenter registry. We also showed a distinct difference in the distribution of the CYP2C19 genotype between Caucasians and Japanese. The incidence of the CYP2C19 loss-of-function allele (*2, or *3) is higher in Japanese than in Caucasians. In short, the distribution of CYP2C19 genotype was 37%, 33%, 11%, 11%, 7%, and 1% in CYP2C19 *1/*1, *1/*2, *1/*3, *2/*2, *2/*3, and *3/*3, respectively. The platelet reactivity level decreased significantly in the wild-type homozygotes (CYP2C19*1/*1), subsequently in the *2, or *3 heterozygotes (*1/*2, *1/*3), and was not well inhibited in the *2, and/or *3 homozygotes (*2/*2, *2/*3, *3/*3). The incidence of cardiovascular events was higher in patients carrying at least 1 loss-of-function allele than in wild-type homozygotes. Bhatt et al indicated in the COGENT trial that drug-drug interaction between PPI and clopidogrel may be stronger in poor metabolizers carrying 2 CYP2C19 loss-of-function alleles and that a much larger study involving genotyping would be necessary. 10 The present study indicates that with the greater prevalence of CYP2C19 lossof-function alleles in Japanese than Caucasians, potential drug interactions cannot exist between clopidogrel and PPI.
The platelet reactivity is increased in early phase of ACS, and clopidogrel responsiveness in patients with ACS is decreased compared with stable angina patients. 23-26 Moreover, there is a possibility that the use of PPI may increase the risk of drug-drug interaction and decrease the antiplatelet PPI After Coronary Stenting efficacy of clopidogrel in ACS. Thus, we performed a subgroup analysis of the ACS patients. As with the finding for the total patient group, concomitant use of PPI and clopidogrel was not associated with an increased risk of cardiovascular events. Although PPI use did not show a reduced risk of gastrointestinal events in ACS, further study including a large number of patients is needed in the future.
In conclusion, PPIs had no increased risk of adverse clinical events after stent implantation.
Study Limitations
This study has important limitations. (1) The use of a PPI was not randomized but was left to the physician's discretion. In contrast to other investigations, however, this study included consecutive patients from a prospective registry, which might have led to less inclusion bias. (2) This study did not show a reduced risk of gastroduodenal lesions by taking a PPI, although there was a tendency toward a higher rate of gastroduodenal events in the non-PPI compared with the PPI group. The low incidence of gastrointestinal events confirmed by endoscopy did not make a significant difference. The small sample size might have affected the power to detect such influence. Moreover, in the elderly who may not complain of upper gastrointestinal symptoms, it is possible to overlook such patients. Thus, further study is needed in the future. (3) Half of patients were in the ticlopidine group, and ticlopidine differs in its metabolism from clopidogrel. 27 Thus, although we performed a subgroup analysis of the clopidogrel arm, we cannot exclude the possibility that inclusion of clopidogrel and ticlopidine might have affected our findings.
